Intravenous Zoledronate for a Patient with Paget's Disease

Paget's disease (PD) of bone is characterized by increase of bone resorption by atypical osteoclasts, followed by rapid new bone formation resulting in a disorganized mosaic bone. Although the pathophysiology is not fully understood, bisphosphonate, which is a potent anti-resorptive agent for t...

Descripción completa

Detalles Bibliográficos
Autor principal: Kim, Ki-Choul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Bone and Mineral Research 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170086/
https://www.ncbi.nlm.nih.gov/pubmed/25247161
http://dx.doi.org/10.11005/jbm.2014.21.3.223
_version_ 1782335786842062848
author Kim, Ki-Choul
author_facet Kim, Ki-Choul
author_sort Kim, Ki-Choul
collection PubMed
description Paget's disease (PD) of bone is characterized by increase of bone resorption by atypical osteoclasts, followed by rapid new bone formation resulting in a disorganized mosaic bone. Although the pathophysiology is not fully understood, bisphosphonate, which is a potent anti-resorptive agent for treatment of osteoporosis, have been the most effective agents available for the treatment of PD. We report a case of PD of bone in a 49-year-old woman patient, who was treated with intravenous zoledronate.
format Online
Article
Text
id pubmed-4170086
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Korean Society for Bone and Mineral Research
record_format MEDLINE/PubMed
spelling pubmed-41700862014-09-22 Intravenous Zoledronate for a Patient with Paget's Disease Kim, Ki-Choul J Bone Metab Case Report Paget's disease (PD) of bone is characterized by increase of bone resorption by atypical osteoclasts, followed by rapid new bone formation resulting in a disorganized mosaic bone. Although the pathophysiology is not fully understood, bisphosphonate, which is a potent anti-resorptive agent for treatment of osteoporosis, have been the most effective agents available for the treatment of PD. We report a case of PD of bone in a 49-year-old woman patient, who was treated with intravenous zoledronate. The Korean Society for Bone and Mineral Research 2014-08 2014-08-31 /pmc/articles/PMC4170086/ /pubmed/25247161 http://dx.doi.org/10.11005/jbm.2014.21.3.223 Text en Copyright © 2014 The Korean Society for Bone and Mineral Research http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kim, Ki-Choul
Intravenous Zoledronate for a Patient with Paget's Disease
title Intravenous Zoledronate for a Patient with Paget's Disease
title_full Intravenous Zoledronate for a Patient with Paget's Disease
title_fullStr Intravenous Zoledronate for a Patient with Paget's Disease
title_full_unstemmed Intravenous Zoledronate for a Patient with Paget's Disease
title_short Intravenous Zoledronate for a Patient with Paget's Disease
title_sort intravenous zoledronate for a patient with paget's disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170086/
https://www.ncbi.nlm.nih.gov/pubmed/25247161
http://dx.doi.org/10.11005/jbm.2014.21.3.223
work_keys_str_mv AT kimkichoul intravenouszoledronateforapatientwithpagetsdisease

Ejemplares similares